Skip to main content
Erschienen in: Supportive Care in Cancer 9/2011

01.09.2011 | Original Article

Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy

verfasst von: Ingrid Stenstrom Ling, Britt Larsson

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pain is a prominent symptom in radiotherapy-induced oral mucositis (OM). This study assesses the effect of pharmacological treatment in head and neck cancer patients with OM-induced pain and swallowing difficulties.

Methods

This study included 82 patients with head and neck cancer undergoing radiotherapy and referred to the Pain and Rehabilitation Centre at Linkoping University Hospital in Sweden because of OM-induced pain. During 1 week, pain assessment, onset of individually tailored choice of drugs, treatment evaluation, and adjustments, were undertaken. Combinations of acetaminophen, non-steroid anti-inflammatory drug (NSAID), and opioids were by steps applied. To evaluate effects, the patients answered the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-head and neck 35 in connection with the initial pain assessment and 1 week later.

Results

Worsening of soreness in mouth and overall worsening of swallowing difficulties were seen in the patients referred within the third week of radiotherapy, showing increased severity of OM during the current week (n = 59). Pain and swallowing difficulties were unchanged in patients referred later than the third week, showing unchanged severity of OM during the current week (n = 23).

Conclusion

The answers to the questionnaire showed that the individualized pain treatment with systemic analgesics exploited to the highest degree was insufficient. Future development of pharmacological possibilities for treatment of OM-related pain is urgent. In addition, development of structured nursing care and patient self-care can contribute to improved pain relief.
Literatur
1.
Zurück zum Zitat Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371:1695–1709PubMedCrossRef Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371:1695–1709PubMedCrossRef
4.
Zurück zum Zitat Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg M (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66(3):253–262. doi:10.1016/S0167-8140(02)00404-8 PubMedCrossRef Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg M (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66(3):253–262. doi:10.​1016/​S0167-8140(02)00404-8 PubMedCrossRef
5.
Zurück zum Zitat Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients with cancer. Dent Clin North Am 52(1):61–77, viiiPubMedCrossRef Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients with cancer. Dent Clin North Am 52(1):61–77, viiiPubMedCrossRef
7.
Zurück zum Zitat Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-inducedmucosal injury, pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025. doi:10.1002/cncr.20162 PubMedCrossRef Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-inducedmucosal injury, pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025. doi:10.​1002/​cncr.​20162 PubMedCrossRef
8.
Zurück zum Zitat Treister N, Sonis S (2007) Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg 15:123–129PubMedCrossRef Treister N, Sonis S (2007) Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg 15:123–129PubMedCrossRef
9.
Zurück zum Zitat Napenas JJ, Shetty KV, Streckfus CF (2007) Oral mucositis: review of pathogenesis, diagnosis, prevention and management. Gen Dent 55(4):335–344PubMed Napenas JJ, Shetty KV, Streckfus CF (2007) Oral mucositis: review of pathogenesis, diagnosis, prevention and management. Gen Dent 55(4):335–344PubMed
14.
Zurück zum Zitat Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis. Cancer 100(9):2026–2046. doi:10.1002/cncr.20163 PubMedCrossRef Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis. Cancer 100(9):2026–2046. doi:10.​1002/​cncr.​20163 PubMedCrossRef
15.
Zurück zum Zitat Silverman S (2007) Diagnosis and management of oral mucositis. J Support Oncol 5(2, Suppl 1):13–21PubMed Silverman S (2007) Diagnosis and management of oral mucositis. J Support Oncol 5(2, Suppl 1):13–21PubMed
17.
Zurück zum Zitat Bensinger W, Schubert M, Ang K-K, Brizel D, Brown E, Eilers J, Elting L, Mittal B, Schattner M, Spielberger R, Treister N, Trotti A (2008) NCCN task force report. Prevention and management of mucositis in cancer care. J Natl Comp Cancer Netw 6(Suppl 1):S1–S21, quiz S22–4 Bensinger W, Schubert M, Ang K-K, Brizel D, Brown E, Eilers J, Elting L, Mittal B, Schattner M, Spielberger R, Treister N, Trotti A (2008) NCCN task force report. Prevention and management of mucositis in cancer care. J Natl Comp Cancer Netw 6(Suppl 1):S1–S21, quiz S22–4
21.
Zurück zum Zitat World Health Organization (1979) Handbook for reporting results of cancer treatment. Geneva, Switzerland, pp 15–22 World Health Organization (1979) Handbook for reporting results of cancer treatment. Geneva, Switzerland, pp 15–22
22.
Zurück zum Zitat Bjordal K, Hammerlid E, Ahlner-Elmqvist M et al (1999) Quality of life in head and neck cancer patients: validation of the European organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 17(3):1008–1019PubMed Bjordal K, Hammerlid E, Ahlner-Elmqvist M et al (1999) Quality of life in head and neck cancer patients: validation of the European organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 17(3):1008–1019PubMed
23.
Zurück zum Zitat Sherman AC, Simonton S, Adams DC et al (2000) Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg 126(4):459–467PubMed Sherman AC, Simonton S, Adams DC et al (2000) Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg 126(4):459–467PubMed
24.
Zurück zum Zitat Murphy B, MD BJ, Isitt J, Garden AS, Gwede CK, Trotti AM, Meridith RF, Epstein JB, Le Q-T, Brizel DM, Bellm LA, Wells N, Cella D (2009) Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage 38(4):522–532. doi:10.1016/j.jpainsymman.2008.12.004 PubMedCrossRef Murphy B, MD BJ, Isitt J, Garden AS, Gwede CK, Trotti AM, Meridith RF, Epstein JB, Le Q-T, Brizel DM, Bellm LA, Wells N, Cella D (2009) Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage 38(4):522–532. doi:10.​1016/​j.​jpainsymman.​2008.​12.​004 PubMedCrossRef
25.
Zurück zum Zitat Epstein JB, Wilkie DJ, Fischer DJ, Kim Y, Villines D (2009) Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol 26(1):1–12. doi:10.1186/1758-3284-1-26, 1 Epstein JB, Wilkie DJ, Fischer DJ, Kim Y, Villines D (2009) Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol 26(1):1–12. doi:10.​1186/​1758-3284-1-26, 1
27.
Zurück zum Zitat Bar Ad V, Weinstein G, Dutta PR, Chalian A, Both S, Quon H (2009) Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. Head Neck 32(2):173–177. doi:10:1002/hed.21165 Bar Ad V, Weinstein G, Dutta PR, Chalian A, Both S, Quon H (2009) Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. Head Neck 32(2):173–177. doi:10:​1002/​hed.​21165
28.
Zurück zum Zitat Raykher A, Correa L, Russo L et al (2009) The role of pretreatment percutaneous endoscopic gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index of the obese patient. J Parenter Enteral Nutr 33(4):404–410. doi:10.1177/0148607108327525 CrossRef Raykher A, Correa L, Russo L et al (2009) The role of pretreatment percutaneous endoscopic gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index of the obese patient. J Parenter Enteral Nutr 33(4):404–410. doi:10.​1177/​0148607108327525​ CrossRef
29.
Metadaten
Titel
Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy
verfasst von
Ingrid Stenstrom Ling
Britt Larsson
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0955-1

Weitere Artikel der Ausgabe 9/2011

Supportive Care in Cancer 9/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.